无创通气与经鼻高流量氧疗:何时选择其一?
该综述比较无创通气(NIV)与经鼻高流量氧疗(HFOT)在急性呼吸衰竭(ARF)中的选择策略。HFOT因耐受性好及高FiO2、PEEP效应和死腔冲洗等生理特点,在ICU新发ARF中可能降低死亡率,或可作一线氧合策略;NIV在慢性呼吸衰竭急性加重伴呼吸性酸中毒中仍是最佳策略,但在新发ARF和免疫抑制患者中需谨慎。两者在术后ARF和拔管后呼吸衰竭预防中可能等效,需更多头对头研究明确适应证。
要点
- ICU新发ARF患者HFOT可能较NIV降低死亡率,或可作一线氧合策略。
- 慢性呼吸衰竭急性加重伴呼吸性酸中毒时NIV仍是最佳氧合策略。
- NIV在新发ARF中因高潮气量可能加重肺损伤,免疫抑制患者中需谨慎。
核心结论
- HFOT在新发ARF中可能优于NIV并作一线氧合策略,NIV在慢性呼吸衰竭急性加重伴呼吸性酸中毒中仍是最佳策略。
研究设计与样本
- 综述,比较NIV与HFOT在急性呼吸衰竭中的选择策略,未报告检索范围与样本量。
主要发现
- HFOT可降低ICU新发ARF患者死亡率(对比NIV)。
- HFOT获益可能与其耐受性好及高FiO2、PEEP效应和连续死腔冲洗减少呼吸功等生理特点有关。
- NIV因压力支持产生高潮气量可能加重既有肺损伤,在新发ARF中需谨慎使用。
- 近期研究报告NIV在免疫抑制ARF患者中无获益甚至有害,但专家仍推荐其作一线策略。
- 近期大规模随机研究提示HFOT在术后ARF治疗或ICU拔管后呼吸衰竭预防中可能等效于NIV。
临床怎么用
- ICU新发ARF可优先考虑HFOT作为氧合策略。
- 慢性呼吸衰竭急性加重伴呼吸性酸中毒应首选NIV。
- 免疫抑制ARF患者使用NIV需权衡专家推荐与近期研究提示的潜在危害。
- 术后ARF或拔管后呼吸衰竭预防中HFOT可作为NIV的等效选择。
局限性
- 现有推荐多基于NIV与标准氧的比较研究,NIV与HFOT头对头研究不足。
- HFOT能否替代标准氧逆转呼吸性酸中毒尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It has been found that high-flow oxygen therapy (HFOT) can reduce mortality of patients admitted to intensive care unit (ICU) for de novo acute respiratory failure (ARF) as compared to non-invasive ventilation (NIV). HFOT might therefore be considered as a first-line strategy of oxygenation in these patients. The beneficial effects of HFOT may be explained by its good tolerance and by physiological characteristics including delivery of high FiO2 , positive end expiratory pressure (PEEP) effect and continuous dead space washout contributing to decreased work of breathing. In contrast, NIV should be used cautiously in patients with de novo ARF due to high tidal volumes promoted by pressure support and that may potentially worsen pre-existing lung injury. Although recent studies have reported no benefit and even deleterious effects of NIV in immunocompromised patients with ARF, the experts have recommended its use as a first-line strategy. In patients with acute-on-chronic respiratory failure and respiratory acidosis, it has been clearly shown that NIV is the best strategy of oxygenation. However, HFOT seems able to reverse respiratory acidosis and further studies are needed to evaluate whether HFOT could represent an alternative to standard oxygen. Although NIV is recommended to treat ARF in post-operative patients or to prevent post-extubation respiratory failure in ICU, recent large-scale randomized studies suggest that HFOT could be equivalent to NIV. While recent recommendations have been established from studies comparing NIV with standard oxygen, new studies are needed to compare NIV versus HFOT in order to better define the appropriate indications for both treatments.
引用
- Frat JP, Coudroy R, Thille AW, et al. Non-invasive ventilation or high-flow oxygen therapy: When to choose one over the other? Respirology. 2018. PMID: 30406954. doi:10.1111/resp.13435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。